Free Cash Flow (Quarterly) Chart

Historical Free Cash Flow (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 4.475B
March 31, 2026 2.803B
December 31, 2025 254.20M
September 30, 2025 6.028B
June 30, 2025 1.283B
March 31, 2025 -1.601B
December 31, 2024 726.60M
September 30, 2024 -458.90M
June 30, 2024 63.40M
March 31, 2024 83.20M
December 31, 2023 -1.963B
September 30, 2023 -1.812B
June 30, 2023 -204.40M
March 31, 2023 827.10M
December 31, 2022 1.024B
September 30, 2022 1.565B
June 30, 2022 369.70M
March 31, 2022 1.642B
December 31, 2021 1.762B
September 30, 2021 1.176B
June 30, 2021 1.244B
March 31, 2021 1.205B
December 31, 2020 995.70M
September 30, 2020 1.392B
June 30, 2020 1.972B
Date Value
March 31, 2020 111.10M
December 31, 2019 1.637B
September 30, 2019 1.169B
June 30, 2019 766.20M
March 31, 2019 -89.30M
December 31, 2018 825.00M
September 30, 2018 1.822B
June 30, 2018 -340.70M
March 31, 2018 200.00M
December 31, 2017 1.25B
September 30, 2017 1.433B
June 30, 2017 1.430B
March 31, 2017 -660.90M
December 31, 2016 1.652B
September 30, 2016 1.432B
June 30, 2016 1.156B
March 31, 2016 -481.20M
December 31, 2015 250.10M
September 30, 2015 781.20M
June 30, 2015 588.70M
March 31, 2015 -473.40M
December 31, 2014 890.70M
September 30, 2014 1.112B
June 30, 2014 752.70M
March 31, 2014 45.30M

Free Cash Flow Definition

Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.

Read full definition.

Free Cash Flow (Quarterly) Range, Past 5 Years

View Free Cash Flow (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow (Quarterly) Benchmarks

View Free Cash Flow (Quarterly) Benchmarks
Start Trial
Johnson & Johnson 7.295B
Merck & Co., Inc. 4.477B
Pfizer Inc. 302.00M
Bristol Myers Squibb Co. 3.088B
Structure Therapeutics, Inc. -120.34M